BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 12926080)

  • 1. Evaluation of a polymorphism in intron 2 of the p53 gene in ovarian cancer patients. From the Danish "Malova" Ovarian Cancer Study.
    Høgdall EV; Kjaer SK; Glud E; Christensen L; Blaakaer J; Vuust J; Bock JE; Norgaard-Pedersen B; Hogdall CK
    Anticancer Res; 2003; 23(4):3397-404. PubMed ID: 12926080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distribution of p53 codon 72 polymorphisms in ovarian tumour patients and their prognostic significance in ovarian cancer patients.
    Høgdall EV; Høgdall CK; Christensen L; Glud E; Blaakaer J; Bock JE; Vuust J; Nørgaard-Pedersen B; Kjaer SK
    Anticancer Res; 2002; 22(3):1859-64. PubMed ID: 12168882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. P53 mutations in tissue from Danish ovarian cancer patients: from the Danish "MALOVA" ovarian cancer study.
    Høgdall EV; Kjaer SK; Blaakaer J; Christensen L; Glud E; Vuust J; Høgdall CK
    Gynecol Oncol; 2006 Jan; 100(1):76-82. PubMed ID: 16183105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of heterozygosity on the X chromosome is an independent prognostic factor in ovarian carcinoma: from the Danish "MALOVA" Ovarian Carcinoma Study.
    Høgdall EV; Ryan A; Kjaer SK; Blaakaer J; Christensen L; Bock JE; Glud E; Jacobs IJ; Høgdall CK
    Cancer; 2004 Jun; 100(11):2387-95. PubMed ID: 15160342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients. From The Danish "MALOVA" Ovarian Cancer Study.
    Høgdall EV; Christensen L; Kjaer SK; Blaakaer J; Kjaerbye-Thygesen A; Gayther S; Jacobs IJ; Høgdall CK
    Gynecol Oncol; 2007 Mar; 104(3):508-15. PubMed ID: 17113137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. P53 mutation does not affect prognosis in ovarian epithelial malignancies.
    Fallows S; Price J; Atkinson RJ; Johnston PG; Hickey I; Russell SE
    J Pathol; 2001 May; 194(1):68-75. PubMed ID: 11329143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study.
    Høgdall EV; Christensen L; Kjaer SK; Blaakaer J; Bock JE; Glud E; Nørgaard-Pedersen B; Høgdall CK
    Cancer; 2003 Jul; 98(1):66-73. PubMed ID: 12833457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prognostic value of pre-operative serum tetranectin, CA-125 and a combined index in women with primary ovarian cancer.
    Høgdall CK; Nørgaard-Pedersen B; Mogensen O
    Anticancer Res; 2002; 22(3):1765-8. PubMed ID: 12168866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distribution of p53 expression in tissue from 774 Danish ovarian tumour patients and its prognostic significance in ovarian carcinomas.
    Høgdall EV; Christensen L; Høgdall CK; Frederiksen K; Gayther S; Blaakaer J; Jacobs IJ; Kjaer SK
    APMIS; 2008 May; 116(5):400-9. PubMed ID: 18452430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients.
    Begum FD; Høgdall CK; Kjaer SK; Christensen L; Blaakaer J; Bock JE; Glud E; Høyer-Hansen G; Ring-Larsen H; Høgdall EV
    Anticancer Res; 2004; 24(3b):1981-5. PubMed ID: 15274388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 allelotypes and enhanced detection of allelic loss in ovarian cancer: lack of correlation with familial and clinical factors.
    Skilling JS; Powills K; Lager DJ; Anderson B; Sorosky J; Buller RE
    Gynecol Oncol; 1996 May; 61(2):180-8. PubMed ID: 8626130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preoperative serum tetranectin, CA125 and menopausal status used as single markers in screening and in a risk assessment index (RAI) in discriminating between benign and malignant ovarian tumors.
    Begum FD; Høgdall E; Kjaer SK; Blaakaer J; Christensen IJ; Christensen L; Høgdall C
    Gynecol Oncol; 2009 May; 113(2):221-7. PubMed ID: 19261323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Mutations of p53 gene exons 5 to 8 in human ovarian cancer and its clinical significance].
    You Z; Guo Y; Wen H
    Zhonghua Fu Chan Ke Za Zhi; 1996 Nov; 31(11):660-3. PubMed ID: 9387525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An investigation of relationships between hypoxia-inducible factor-1 alpha gene polymorphisms and ovarian, cervical and endometrial cancers.
    Konac E; Onen HI; Metindir J; Alp E; Biri AA; Ekmekci A
    Cancer Detect Prev; 2007; 31(2):102-9. PubMed ID: 17418979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. APC, K-ras, and p53 gene mutations in colorectal cancer patients: correlation to clinicopathologic features and postoperative surveillance.
    Hsieh JS; Lin SR; Chang MY; Chen FM; Lu CY; Huang TJ; Huang YS; Huang CJ; Wang JY
    Am Surg; 2005 Apr; 71(4):336-43. PubMed ID: 15943410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. P53 gene status in patients with advanced serous epithelial ovarian cancer in relation to response to paclitaxel- plus platinum-based chemotherapy and long-term clinical outcome.
    Gadducci A; Di Cristofano C; Zavaglia M; Giusti L; Menicagli M; Cosio S; Naccarato AG; Genazzani AR; Bevilacqua G; Cavazzana AO
    Anticancer Res; 2006; 26(1B):687-93. PubMed ID: 16739339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Detection and sequence analysis of the p53 gene mutation in epithelial ovarian cancer].
    Guan X; Lang J; Bian M
    Zhonghua Fu Chan Ke Za Zhi; 1998 Mar; 33(3):165-7. PubMed ID: 10682487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prognostic value of pretherapeutic tetranectin and CA-125 in patients with relapse of ovarian cancer.
    Deng X; Høgdall EV; Høgdall CK; Nørgaard-Pedersen B; Jørgensen M; Nielsen H; Engelholm SA
    Gynecol Oncol; 2000 Dec; 79(3):416-9. PubMed ID: 11104612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53 tumor suppressor gene mutation in ovarian cancer in Thai patients.
    Neungton N; Neungton S; Leelaphatanadit C; Dangrat C; Soiampornkul R
    J Med Assoc Thai; 2002 Jun; 85(6):658-67. PubMed ID: 12322838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum tetranectin as a preoperative indicator for postoperative complications in Danish ovarian cancer patients.
    Begum FD; Høgdall E; Christensen IJ; Christensen L; Kjaer SK; Blaakaer J; Petri AL; Høgdall C
    Gynecol Oncol; 2010 Jun; 117(3):446-50. PubMed ID: 20304468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.